You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/111183
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMello Ayres Putinatti, Maria Stella de-
dc.contributor.authorLastoria, Joel Carlos-
dc.contributor.authorPadovani, Carlos Roberto-
dc.date.accessioned2014-12-03T13:07:02Z-
dc.date.accessioned2016-10-25T19:48:08Z-
dc.date.available2014-12-03T13:07:02Z-
dc.date.available2016-10-25T19:48:08Z-
dc.date.issued2014-03-01-
dc.identifierhttp://dx.doi.org/10.1590/abd1806-4841.20142037-
dc.identifier.citationAnais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 89, n. 2, p. 266-272, 2014.-
dc.identifier.issn0365-0596-
dc.identifier.urihttp://hdl.handle.net/11449/111183-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/111183-
dc.description.abstractBACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL.en
dc.format.extent266-272-
dc.language.isoeng-
dc.publisherSoc Brasileira Dermatologia-
dc.sourceWeb of Science-
dc.subjectErythema nodosumen
dc.subjectLeprosyen
dc.subjectMedication therapy managementen
dc.subjectThalidomideen
dc.titlePrevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/dayen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationUniv Estadual Paulista Julio de Mesquita Filho Un, Botucatu, SP, Brazil-
dc.description.affiliationUnespUniv Estadual Paulista Julio de Mesquita Filho Un, Botucatu, SP, Brazil-
dc.identifier.doi10.1590/abd1806-4841.20142037-
dc.identifier.scieloS0365-05962014000200266-
dc.identifier.wosWOS:000335171600009-
dc.rights.accessRightsAcesso aberto-
dc.identifier.fileS0365-05962014000200266.pdf-
dc.relation.ispartofAnais Brasileiros de Dermatologia-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.